Back to Journals » Drug Design, Development and Therapy » Volume 5 » default

Drug Design, Development and Therapy


Archive: Volume 5, 2011

Profile of ipilimumab and its role in the treatment of metastatic melanoma

Patel SP, Woodman SE

Drug Design, Development and Therapy 2011, 5:489-495

Published Date: 16 December 2011

Corrigendum

Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-Cruz IM

Drug Design, Development and Therapy 2011, 5:487-488

Published Date: 28 November 2011

The influence of operational parameters and feed preparation in a convective batch ribbon powder mixer

Yeow ST, Shahar A, Abdul Aziz N, Anuar MS, Yusof YA, Taip FS

Drug Design, Development and Therapy 2011, 5:465-469

Published Date: 14 November 2011

Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release

Benedek IH, Jobes J, Xiang Q, Fiske WD

Drug Design, Development and Therapy 2011, 5:455-463

Published Date: 31 October 2011

Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates

Muratore M, Quarta E, Grimaldi A, Calcagnile F, Quarta L

Drug Design, Development and Therapy 2011, 5:445-454

Published Date: 19 October 2011

Future prospects in the treatment of erectile dysfunction: focus on avanafil

Alwaal A, Al-Mannie R, Carrier S

Drug Design, Development and Therapy 2011, 5:435-443

Published Date: 18 October 2011

Bioequivalence assessment of two formulations of ibuprofen

Al-Talla ZA, Akrawi SH, Tolley LT, Sioud SH, Zaater MF, Emwas AHM

Drug Design, Development and Therapy 2011, 5:427-433

Published Date: 19 October 2011

Investigation of the antibacterial activity of pioglitazone

Masadeh MM, Mhaidat NM, Al-Azzam SI, Alzoubi KH

Drug Design, Development and Therapy 2011, 5:421-425

Published Date: 27 September 2011

Emerging options in growth hormone therapy: an update

Kemp SF, Frindik JP

Drug Design, Development and Therapy 2011, 5:411-419

Published Date: 30 August 2011

Effect of surfactant and surfactant blends on pseudoternary phase diagram behavior of newly synthesized palm kernel oil esters

Mahdi ES, Sakeena MH, Abdulkarim MF, Abdullah GZ, Sattar MA, Noor AM

Drug Design, Development and Therapy 2011, 5:311-323

Published Date: 1 June 2011

Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus

Kawai Y, Sato-Ishida R, Motoyama A, Kajinami K

Drug Design, Development and Therapy 2011, 5:283-297

Published Date: 11 May 2011

Development of oral immunomodulatory agents in the management of multiple sclerosis

Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PA

Drug Design, Development and Therapy 2011, 5:255-274

Published Date: 10 May 2011

Targeting nicotine addiction: the possibility of a therapeutic vaccine

Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-Cruz IM

Drug Design, Development and Therapy 2011, 5:211-224

Published Date: 18 April 2011

Current and emerging drugs for the treatment of inflammatory bowel disease

Triantafillidis JK, Merikas E, Georgopoulos F

Drug Design, Development and Therapy 2011, 5:185-210

Published Date: 6 April 2011

Corrigendum

Channing J Paller, Emmanuel S Antonarakis

Drug Design, Development and Therapy 2011, 5:183-184

Published Date: 21 March 2011

Drug discovery and development for neglected diseases: the DNDi model

Eric Chatelain, Jean-Robert Ioset

Drug Design, Development and Therapy 2011, 5:175-181

Published Date: 16 March 2011

Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel

Andrew S Bomback, James A Tumlin, Joel Baranski, et al

Drug Design, Development and Therapy 2011, 5:147-153

Published Date: 14 March 2011

Paliperidone extended-release: does it have a place in antipsychotic therapy?

Maximilian Gahr, Markus A Kölle, Carlos Schönfeldt-Lecuona, et al

Drug Design, Development and Therapy 2011, 5:125-146

Published Date: 11 March 2011

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer

Channing J Paller, Emmanuel S Antonarakis

Drug Design, Development and Therapy 2011, 5:117-124

Published Date: 10 March 2011

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine

Lilliana Oliveira, Russell D Cohen

Drug Design, Development and Therapy 2011, 5:111-116

Published Date: 27 February 2011

The use of serotonergic drugs to treat obesity – is there any hope?

Nicholas T Bello, Nu-Chu Liang

Drug Design, Development and Therapy 2011, 5:95-109

Published Date: 10 February 2011

Cefditoren in upper and lower community-acquired respiratory tract infections

Francisco Soriano, María-José Giménez, Lorenzo Aguilar

Drug Design, Development and Therapy 2011, 5:85-94

Published Date: 9 February 2011

Illicit methylphenidate use among Iranian medical students: prevalence and knowledge

Afshin Habibzadeh Mahasti Alizadeh Ayoub Malek, et al

Drug Design, Development and Therapy 2011, 5:71-76

Published Date: 3 February 2011

Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab

Ignacio Garcia-Valladares, Raquel Cuchacovich, Luis R Espinoza

Drug Design, Development and Therapy 2011, 5:41-49

Published Date: 10 January 2011

Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation

Patrick A Schweizer, Rüdiger Becker, Hugo A Katus, et al

Drug Design, Development and Therapy 2011, 5:27-39

Published Date: 6 January 2011

Current progress in the development of a prophylactic vaccine for HIV-1

Lena J Gamble, Qiana L Matthews

Drug Design, Development and Therapy 2011, 5:9-26

Published Date: 22 December 2010